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Abstract
The etiology and pathogenesis of malignant tumor growth are associated with 
impaired gene expression, leading to accelerated proliferation, evasion of 
apoptosis, and metabolic deregulations with abnormal blood supply and inner-
vation. Currently, hundreds of tumor suppressor genes and proto-oncogenes 
are known. Mutations, epigenetic alterations, exposure to viruses, and other 
environmental factors can cause pathological changes in gene expression. The 
key mechanisms of carcinogenesis are now considered to be linked to epigene-
tic events. A better understanding of epigenetic targets and pathways is needed 
to develop new strategies in antitumor chemotherapy. The majority of modern 
cancer drugs were taken from nature, yet only a small fraction of natural mo-
lecular diversity has been explored to date. Therefore, there is great interest in 
identifying new natural molecules for modulating gene expression by rewiring 
epigenetic pathways. This review is focused on examples of known natural mol-
ecules available to biomedicine, especially ones capable of modulating epigen-
etic landscapes and therefore relevant for cancer prevention and aging.
Keywords: cancer, aging, natural products, silencing, methylation, histone 
modification, signaling pathways
Epigenetic	regulation	and	chromatin
Epigenetic processes include changes in gene expression that happen irrespec-
tively of alterations in DNA sequences (Schubert et al., 2015). The outcomes may 
have contrasting functional consequences depending on the structural organi-
zation of chromatin. For example, “open chromatin”, called euchromatin, pro-
motes gene expression, while heterochromatin (“closed chromatin”) suppresses it 
(Sutherland et al., 2003). Furthermore, heterochromatin is involved in processes 
of dosage compensation, allelic imprinting, cell- and tissue-specific gene expres-
sion, and many other aspects of molecular cell biology, which are being actively 
researched in the last few decades. Substantial heterochromatin domains span 
arrays of hundreds and thousands of repeated elements as integral elements of 
functional centromeres in most eukaryotes (Buscaino et al., 2010). As a rule, these 
heterochromatic regions in most genomes lack active genes, and the transcription 
of genes located in the heterochromatin is inhibited because the resident DNA 
sequences attract chromatin-modifying activities that counteract functional as-
sembly of the transcription machinery (Huisinga et al., 2006; Grewal et al., 2007). 
However, while the formation of heterochromatin on repetitive elements makes 
these regions transcriptionally inert, it promotes genome stability by regulating 
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recombination, DNA repair, and chromosome segre-
gation (Grewal et al., 2007). Recent experiments have 
made it possible to model gene expression, taking into 
account many factors, including nucleosome dynam-
ics and binding of activators and repressors (Teif et al., 
2011). Moreover, loss of gene expression, called epigene-
tic gene silencing, is one of the most frequently observed 
mechanisms exploited by cancer in order to modulate 
cell fates (Urnov et al., 2001).
DNA methylation is the most widely studied epigen-
etic mark, and it plays important roles in regulating gene 
expression and maintaining genome stability in a spec-
trum of species including plants, rodents, and humans 
(Weber et al., 2007; Qian et al., 2014; Xu et al., 2015). 
DNA methylation in general is defined as a biochemical 
process whereby a methyl group is added to DNA bases. 
It usually occurs on the fifth position of cytosine (C) to 
form 5-methyl cytosine, known as 5mC in the context 
of CpG dinucleotides — regions of DNA where a cyto-
sine is followed by a guanine along the 5′→3′ direction 
in both eukaryotes and prokaryotes (Weber et al., 2007; 
Qian et al., 2014; Xu et al., 2015).
The effect of 5mC is traditionally considered to in-
terfere with transcriptional initiation, which thereby si-
lences gene expression (Jones et al., 1999).
Posttranslational modifications of proteins are one 
of the main determinants of genomic functions, provid-
ing a fast, controlled and reversible response to environ-
mental signals (Khoury et al., 2011). Such modifications 
can be caused by phosphorylation, nitrosylation, meth-
ylation, ubiquitylation, sumoylation, and other chemical 
reactions, with the most well studied ones being acetyla-
tion and methylation (Choudhary et al., 2014). Adding 
acetyl groups to the lysine residues in the protein is cata-
lyzed by lysine acetyl transferases changing the charge 
and structure of the molecule, leading to a change in its 
function (Azevedo et al., 2016). In the last two decades, 
the acetylation of histone molecules (by histone acetyl 
transferases, HATs) was attracting particular interest 
and has been shown to be involved in the complex com-
binatorial regulation of local genome properties such 
as transcription, DNA repair and other chromosomal 
transactions. Histone deacetylases (HDACs) comprise 
a class of enzymes, reversing acetylations, responsible 
for epigenetic regulation of gene expression and playing 
critical roles in cellular processes including cell prolif-
eration, apoptosis, differentiation, and angiogenesis. 
Methylation of histones can be either repressive in rela-
tion to transcription — such as methylation of histone 
H3  lysine-9  methylation (H3K9me), which dominates 
heterochromatic areas  — or transcription-promoting 
(e.g., H3K4me) (Rea et al., 2000; Jenuwein et al., 2001). 
Methylation of H3K9  allows binding of specific chro-
modomain proteins, including HP1  (heterochromatin 
protein 1) variant, which interact with various key chro-
matin modifying activities (Bannister et al., 2001; Na-
kayama et al., 2001). Table 1 gives a list of modifications, 
mostly acetylation and methylation, that sometimes are 
referred to as a histone code.
Of the many diseases that can be associated with 
epigenetic deregulations, the most common and widely 
studied are cancers. Cancer can occur due to the activa-
tion of oncogenes and/or repression of tumor suppres-
sors. Numerous clinical and experimental data suggest 
that tumor cells generally exhibit genome-wide hypo-
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to normal cells. Interactions between DNMTs and his-
tone methyltransferases, such as EZH2 and SETD2, play 
critical roles in epigenetic disruption during malignancy 
(Wu Zhang et al., 2017). Mechanisms by which overex-
pression of histone demethylase LSD1 leads or contrib-
utes to tumor formation could involve its capacity to 
silence tumor suppressor genes as a transcriptional co-
repressor, mainly through H3K4 demethylation. In ad-
dition, non-coding RNAs, e.g., micro-RNAs (miRNAs), 
and long non-coding RNAs (lncRNAs) were the focus of 
attention in terms of epigenetic control. With the devel-
opment of RNA sequencing methodologies, a number 
of such non-coding RNAs were identified and charac-










Biological effects of  
HDAC inhibitors Mechanisms of their implementation
Cell cycle arrest at G1/S or 
G2/M⁄ phases
Induction of CDKN1A to encode p21waf1/CIP1 promoting pRb hypo-phosphorylation
Repression of genes, Cyclin D and Cyclin A, to reduce CDK2 and CDK4 kinase activities and 
hypophosphorylation of pRb
Induction of p27 which inhibits CDK2- and CDK4-containing complexes
Repression of genes for DNA synthesis, CTP synthase and thymidylate synthetase
Activation of G2-phase checkpoint through heterochromatin hyperacetylation leads to abnormal 
chromosomal segregation and fragmentation of nucleus
Oxidative stress and DNA 
damage
Accumulation of ROS in tumor cells to induce mitochondrial disruption
Downregulation of TrX (scavenger of ROS)
Indirect DNA damage by increased accumulation of phosphorylated histone variant, cH2AX (marker of DSB in DNA)
Repression of genes for DNA repair proteins, RAD51, BRAC1, BRCA2, Ku70 and Ku86
External pathway of 
mediated apoptosis
Upregulation of TRAIL, DR5, Fas, Fas-L and TNFain transformed tumor cells; thus activation of Casp 8 and 10
Repression of genes encoding for DR inhibitors, FLIP and IAP2
Mitochondrial pathway of 
mediated apoptosis
Upregulating expression of pro-apoptotic (anti-survival) proteins of BCL2 family, namely Bid, Bim, Bmf
Downregulation of expression of anti-apoptotic (pro-survival) BCL2 family proteins (BCL2, BCL-XL, BCL-w), 
MCL-1 and XIAP
Gene induction for encoding mediators causing mitochondrial damage (Diablo, Casp 9, Apaf1, Cyt C and Htr A2)
Autophagy and aging
Overexpression of BCL-XL thereby inducing autophagy-mediated cell death
Aging through polyploidy and withdrawal of cell cycle
Anti-angiogenesis
Repression of pro-angiogenesis factors, HIF-1a, VEGF and CXCR4
Upregulation of tumor suppressor VHL protein and p53
Immunomodulation
Augmenting tumor cell antigenicity by upregulating MHC class I and II proteins, costimulatory molecules 
(CD40, CD80 and CD86) and ICAM1
Inducing expression of MHC class I chain-related molecules, MICA and MICB
Suppression in secretion of pro-inflammatory cytokines, TNF a, IL-1 and IFNc
Non-histone substrate 
mediated
Hyperacetylation of transcription factors, E2F1, p53, STAT1, STAT3 and NF-jB
Hyperacetylation of proteins, Hsp90, a-tubulin, to induce protein degradation, cell growth inhibition, cell death
Disruption of HDAC-PP1 complexes and activation of PP1 to cause irregularity in tumor cell phosphorylation 
and acetylation
Disruption of aggresome pathway for degradation of misfolded protein aggregates
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has complicated the paradigm of epigenetic landscapes, 
suggesting the role of lipids in gene regulation (Zhdanov 
et al., 2015), as well as the discovery of chromatin factors 
involved in both repression and activation. For example, 
H3.3, a histone variant of H3, is commonly associated 
with transcription activation (Ahmad et al., 2002).
Unlike genetic mutations, epigenetic changes can be 
reversible. This reversibility led to the emergence of the 
concept of “epigenetic therapy”, according to which the 
reactivation of epigenetically silent tumor suppressor 
genes can restore growth control in cancer cells (Jones et 
al., 2007; Marks 2010; Santos et al., 2010; Taby et al., 2010). 
As noted earlier, histone acetylation and deacetylation are 
catalyzed by specialized enzymes, namely histone (lysine) 
acetyltransferases (HATs/KATs) and HDACs, which af-
fect specific tissues and genomic contexts differently 
(Chen et al., 2015; Venkatasubramani et al., 2015). It has 
long been established that many cancers are characterized 
by global hypoacetylation of histones (Fraga et al., 2005). 
Overexpression of individual HDACs is associated with 
reduced survival rates in numerous tumors, including co-
lon, breast, lung and prostate cancer (West et al., 2014). 
In addition, the genetic knockdown of specific HDACs in 
these tumors caused cell cycle arrest and apoptosis.
Multiple biological effects of HDAC inhibitors are 
presented in Table 2.
As a result, numerous HDAC inhibitors have been 
clinically tested, and some have recently been approved by 
the FDA for use in various forms of human cancer (Ma et 
al., 2016). It is hoped that these HDAC inhibitors can be 
used in tumors that have developed resistance to conven-
tional treatments or after a relapse of primary cancer (Bo-
jang et al., 2014). It has been clearly demonstrated that the 
patterns of global acetylation of H3 and H4 correlate with 
the severity of prostate and other cancers, (Seligson et al., 
2005) while global methylation patterns may have diag-
nostic and prognostic potential for a number of different 
tumors (Lizcano et al., 2012). Recently, the main efforts 
of epigenetic therapy were aimed to develop and refine 
inhibitors of two families of HDACs and DNMTs (Jones 
et al., 2007; Taby et al., 2010; Li-Ting Wang et al., 2014).
Natural	modulators	of	cellular	pathways
Natural compounds are a key source of drugs in mod-
ern biomedicine (Neergheen-Bhujun et al., 2017). Vari-
ous types of natural molecules inhibiting silencing can 
be considered a fruitful avenue both for chemotherapy 
of cancers and for aging control. In the first part of our 
review we extensively cover the existing literature and 
perspectives concerning these types of molecules. In the 
second part we summarize other potentially interesting 
enzymes and their inhibitors that may join the therapeu-
tic repertoire in the future. Recently it has been proved 
that natural compounds such as curcumin, epigallo-
catechin gallate and resveratrol could alter epigenetic 
mechanisms which can lead to increased sensitivity of 
cancer cells to conventional agents and thus inhibit tu-
mor growth (Li et al., 2010). A number of studies have 
reported on curcumin effects on HDAC expression. It is 
known that curcumin is also a potent HDAC inhibitor, 
which is more effective than valproic acid and sodium 
butyrate (Bora-Tatar et al., 2009). Another study has re-
ported that levels of HDAC 1, 3, and 8 were significant-
ly reduced by curcumin, leading to increased levels of 
acetylated histone H4 (Liu et al., 2005). Similarly, a sig-
nificant reduction in HDAC1 and HDAC3 was observed 
upon treatment with curcumin (Chen et al., 2007).
Currently, more than 60 % of the FDA-approved anti-
cancer drugs are derived from natural compounds isolat-
ed from various types of organisms (Neergheen-Bhujun et 
al., 2017). These include plants (e.g., vincristine, vinblas-
tine, etoposide, paclitaxel, camptothecin, topotecan, and 
irinotecan), marine organisms (e.g., cytarabine, aplidine, 
and dolastatin), and microorganisms (e.g., dactinomycin, 
bleomycin, and doxorubicin). A number of natural com-
pounds relevant to cancer prevention and/or therapy have 
been derived from fruits and vegetables. These include: 
curcumin (from turmeric), resveratrol (from red grapes, 
peanuts, and berries), genistein (from soy), diallylsulfide, 
S-allylcysteine and allicin (from garlic), lycopene (from 
tomatoes), capsaicin (from chili peppers), diosgenin 
(from fenugreek), 6-gingerol (from ginger), ellagic acid 
(from pomegranates), ursolic acid (from apples, pears, 
prunes, etc), silymarin (from milk thistle), anetol (from 
anise, camphor, or dill), catechins and Epigallocatechin 
gallate (EGCG) (from green tea), eugenol (from cloves), 
indole-3-carbinol (from cruciferous waxes), and many 
others (Bhanot et al., 2011; Pratheeshkumar et al., 2012; 
Craig et al., 2013; Wai-Leng et al., 2013; Bailon-Moscoso 
et al., 2017). It has been shown that these natural com-
pounds may change localized and global gene expression, 
induce apoptosis, or affect the activity of ligand-depen-
dent receptor activators and oxidative stress modulators, 
leading to cell cycle shutdown, necrosis, and autophagy 
(Kong et al., 2012; Pratheeshkumar et al., 2012; Shukla 
et al., 2014). A number of studies have shown that cur-
cumin, EGCG, resveratrol, sulforaphane, Gallic acid, 
genistein, 3,3’-diindolylmethane, and other natural mol-
ecules alter epigenetic processes, including DNA meth-
ylation, histone modification, chromatin remodeling, 
microRNA regulation, and thereby, cell fates. Examples 
of identified protein targets of such molecules include the 
activator Protein 1  (AP-1), Inhibitor of Differentiation 
4 (ID4), Nuclear Factor-kappaB (NF-κB)/REL-A, Signal 
Transducer and Activator of Transcription (STAT)-3, 
5 and 6, MYC, Runt-related transcription factor (RUNX)-
1, NOTCH1-4, CCAAT/Enhancer Binding Protein al-
pha (C/EBPα), β-catenin (CTNNB1), Sterol Regulatory 
Element-Binding Protein (SREBP)-1c, members of Tu-









mor Protein (TP)-p53 family Interferon Regulatory Fac-
tor (IRF)-5, SMAD4, GLI factors, Krüppel-Like Factor 
(KLF)-5, MIcrophthalmia-associated Transcription Fac-
tor (MITF), PAX family members, TWIST, and Wilms’ 
Tumor factor 1 (Lee, 2007; Kikuno et al., 2008; Andreoli 
et al., 2010; Lee et al., 2010; Tuntiwechapikul et al., 2010; 
Chen et al., 2011; Fujiwara Komohara et al., 2011; Li et al., 
2011; Lee et al., 2013;). 
Alkaloids and polyphenols are the predominant mol-
ecules in use for the treatment of cancer. Many natural 
polyphenols have cytostatic and apoptotic properties due 
to their antioxidant characteristics. Anti-carcinogenic ac-
tivity of polyphenols includes suppression of proliferation, 
differentiation, metastasis, and angiogenesis of various 
types of cancer cells through inhibition of several kinases 
involved in signal transduction. Polyphenols can easily 
bind and cross cell membranes and interfere with vari-
ous molecular mechanisms in the cell, including caspases, 
B cell lymphoma 2  (Bcl-2)  family proteins, nuclear fac-
tor (NF)-kB, epidermal growth factor (EGF)/epidermal 
growth factor receptor (EGFR), phosphatidylinositol-
3-kinase (PI3K)/Akt, mitogen-activated protein kinase 
(MAPK) (Li-rui Sun et al., 2019) (Fig. 1).
We will next discuss some of the natural compounds 
and their targets in detail.
Curcumin,	EGCG,	and	Reservatrol	and	
epigenetic regulation
Curcumin (diferuloylmethane), a polyphenol from 
Curcuma longa, inhibits tumor cell growth and induces 
tumor cell death. Moreover, curcumin could modulate 
various signaling pathways involved with inflammation, 
proliferation, invasion, survival, and apoptosis (Huang 
et al., 1997; Teiten et al., 2010). It has been shown that 
curcumin induces p63  and MYC-associated factor X 
(MAX), and also inhibits NF-κB in hepatocarcinoma 
cells and OCT4  in pluripotent cells of embryonal car-
cinoma of the placenta (NCCIT). Some scientists sug-
gest that these genes could act as potential therapeu-
tic targets, especially in cancer stem cells. (Zang et 
al., .2014; Marquardt et al., 2015). Recent studies have 
found that curcumin lowers the activity of NF-κB and 
NOTCH1 in human hematopoietic Raji cells by inhibit-
ing the interaction of histone deacetylases (e.g., HDAC1, 
HDAC3)  with E1A-binding protein 300  (EP300) and 
their binding with cAMP response element. Also, cur-
cumin could modulate the expression of transcription 
factor components AP-1, c-FOS, and c-JUN (Muk-
hopadhyay et al., 2001; Park et al., 2005; Prusty et al., 
2005; Chen et al., 2007; Lin et al., .2007). Curcumin had 
caused DNA damage and led to apoptosis in p73  and 
p53-deficient human hepatoma cells Hep3B (Wang et 
al., .2015). It was found that curcumin induces global 
and sequence-specific demethylation of the epigeneti-
cally silenced genes in human leukemia cells (Liu et al., 
2009). Consistent with this, an in silico study has shown 
that curcumin could covalently block the catalytic thiol 
group in the C1226 DNMT1 binding site (Medina-Fran-
co et al., 2011).
Tea polyphenols isolated from green tea Camel-
lia sinensis include epicatechin, epicatechin-3-gallate 
(EGCG), epigallocatechin and epigallocatechin-3-gal-
late. Epicatechin gallate induced tumor cell death by 
activating TP53 and stimulating mitogen-activated pro-
tein kinase p38 (MAPK) and c-Jun N-terminal kinases 
Polyphenols
















Inhibition of several kinases
involved in the signal transduction
Suppressing the proliferation, dierentiation,
metastasis and angiogenesis of cancer cells
MicroRNAs (miRNAs)
caspases




(EGF) / epidermal growth
factor receptor (EGFR)
Phosphatidylinositol-3-
kinase (PI3K) / Akt
Mitogen-activated protein
kinase (MARK)
Fig. 1. The signaling pathways of polyphenols in cancer.
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(JNK) in human colon cancer cells in vitro (Cordero-
Herrera et al., 2013). The main polyphenols in black tea 
are: catechins, flavonoids, methylxanthines, theaflavins, 
and thearubigins (Siddiqui et al., 2006). The compound 
Polyphenon-B, isolated from black tea, suppressed the 
growth of hepatocellular carcinomas in rats (induced by 
3,3’-diaminobenzidine), while simultaneously reducing 
the expression of hypoxia-induced factor (HIF) –1α and 
increasing HDAC1 levels (Murugan et al., 2009). Several 
studies have reported the inhibitory effects of tea poly-
phenols on DNA methylation in ovarian, oral, esopha-
geal, breast, stomach, prostate, skin, colorectal, pancre-
atic and head and neck cancers. (Fang et al., 2007; Dou, 
2009; Link et al., 2010; Pandey et al., 2010; Ho E. et al., 
2011; Henning et al., 2012, 2013; Gerhauser, 2013; Saha 
et al., 2013). 
Recent structural and molecular modeling studies 
have shown that the structures of D — and B-cycles of 
tea polyphenols (EGCG, for example) inhibit the DN-
MTs activity (Lee et al., 2005). It has been shown that 
EGCG bind Pro-1223, Glu-1265, Cys-1225, Ser-1229, 
and Arg-1309  in the catalytic pocket of DNMT1  pro-
tein. (Lee et al., 2005; Thakur et al., 2014). Catechol-
containing polyphenols inhibit DNMTs by increasing 
the o-methylation of SAM by the enzyme catechol-O-
methyltransferase, direct inhibition of the enzyme di-
hydrofolate reductase activity, disruption of the folate 
cycle and increased SAM levels, and direct inhibition 
of DNMTs [Lee et al., 2005; Thakur et al., 2014). It has 
been reported that EGCG reverse hypermethylation of 
Cdkn2a, retinoic acid receptor-β (Rarß), O-6-methyl-
guanine-DNA-methyltransferase (MGMT), and MutL 
Homolog-1 (MLH1) genes by inhibiting DNMT1 activ-
ity in human esophageal cancer KY55 cells by binding 
to the DNMT1  catalytic pocket and by inhibiting its 
enzyme activity (Lu et al., 2007; Xiao et al., 2007; Gao 
et al., 2009). Also, EGCG inhibits DNMTs activity and 
reactivate the Rarß gene suppressed by methylation in 
human colon and prostate cancer cells (Lee et al., 2005). 
EGCG could demethylate the promoter regions of DNA 
of genes encoding annexin A1  (ANXA1)  and inhibit 
Wnt1(WIF1) factor in lung cancer cells (Lu et al., 2007; 
Xiao et al., 2007; Gao et al., 2009). Exposure of human 
epidermoid carcinoma A431  cells to EGCG decreased 
global levels of DNA methylation and activity and 
DNMT proteins DNMT1, DNMT3A, and DNMT3B 
(Nandakumar et al., 2011). At the same time, it was dis-
covered that EGCG reactivated silenced CDKN1A and 
CDKN2A (Nandakumar et al., 2011). Effects of green 
tea-derived EGCG have been demonstrated in cancer 
cells of the esophagus, oral cavity, skin, lungs, breast, 
and prostate cancer models (Henning et al., 2013). Tran-
scription factors (e.g., NF-κB, AP-1, CREB, and HIF-1α) 
were suppressed in mouse melanoma cells when treated 
with a combination of EGCG with dacarbazine or quer-
cetin with sulforaphane (Liu et al., 2001; Pradhan et al., 
2010; AlQathama et al., 2015; Feitelson et al., 2015).
Resveratrol [3, 5, 4’-trihydroxy-trans-stilbene] is a 
natural polyphenol from blueberries, mulberries, cran-
berries, peanuts, and grapes. It was shown that resvera-
trol has a pronounced anticancer potential. Resveratrol 
inhibits the transmission of Hif1a-mediated androgen 
receptor signals and reduces the proliferation of prostate 
cancer cells in vitro and tumor progression in vivo (Mi-
tani et al., 2014). A recent study showed that resveratrol 
works to inhibit the development of pancreatic cancer 
in KRAS mutant mice (Shankar et al., 2011). It has been 
further discovered that resveratrol induces apoptosis 
in human cancer stem cells, activating caspase-3/7 and 
inhibiting the expression of BCL-2  and XIAP proteins 
(Shankar et al., 2011; Wang et al., 2013). Resveratrol 
inhibits the expression of metastasis associated pro-
tein-1 (MTA1), a known component of the nucleosome 
remodeling and deacetylation complex NuRD, which is 
overexpressed in some cancer types, including prostate 
cancer (Kai et al., 2010; Dhar et al., 2015; Levenson et 
al., 2015). As a result of MTA1  expression inhibition, 
resveratrol interfered with MTA1 / HDAC1 interaction 
in the NuRD co-repressor complex, causing increased 
TP53  expression and acetylation, which subsequently 
led to an increase in Bax and p21  expression, leading 
to apoptosis in prostate cancer cells (Kai et al., 2010; 
Levenson et al., 2014; Dhar et al., 2015). Pterostilbene 
found in blueberries, a natural resveratrol derivative, 
has also been found to greatly increase the MTA1-me-
diated TP53 acetylation (Li et al., 2013). Resveratrol and 
pterostilbene were also found to suppress tumor growth, 
progression, local invasion, and spontaneous metasta-
ses in orthotopic prostate cancer xenografts in another 
study (Li et al., 2013). Resveratrol inhibited HDAC1, 
HDAC2, MTA1, MTA2, and MTA3 proteins of NuRD 
complex in prostate cancer DU145  cells and activated 
the PTEN tumor suppressor by increasing its acetyla-
tion, which led to the inhibition of the AKT signaling 
pathway in prostate cancer (Levenson et al., 2014; Dhar 
et al., 2015). It has been further shown that resvera-
trol induces autophagy by activating NAD-dependent 
deacetylase, SIRT1  (Cherblanc et al., 2013). However, 
other phenolic compounds found in red wine, includ-
ing anthocyanins (ENIN), stilbenoid (piceatannol), 
phenols (gallic acid), glycosides (delphinidin, kuronen, 
peonidin), and flavonoids (catechin, epicatechin, quer-
cetin, myrinet) were also shown to promote autophagy 
(Pietrocola et al., 2012). Resveratrol is selective for the 
class III HDACs such as SIRT1, SIRT2, SIRT3, as well as 
for the HAT, EP300 (Pietrocola et al., 2012). Also, resve-
ratrol could induce prostate cancer cell death in vitro by 
the modulation of global gene expression rates through 
deacetylation of FOXO transcription factor in human 
pancreatic and prostate cancer cells in vitro and in vivo 









(Chen et al., 2010; Ganapathy et al., 2010; Roy et al., 
2011). Stemness transcription factors, namely NANOG, 
SOX2, c-MYC, and OCT4, were also inhibited by resve-
ratrol, curcumin, and epigallocatechin-3-gallate in hu-
man cancer stem cells (Shankar et al., 2011; Ding et al., 
2013; Wang et al., 2013; Yoon et al., 2014).
Effects of natural compounds on epigenetic and an-
titumor activity are shown in Table 3.
Rapamycin,	metformin,	and	aging
For a long time, aging was considered an unforgiving 
road to decline and disease, but more recently, with the 
advancement of molecular and cellular insight into biol-
ogy of the related processes, it is becoming evident that 
aging is plastic. Such plasticity could be used to approach 
aging of an organism and age-related diseases from a new 
perspective. In particular, aging is associated with deep 
epigenetic changes leading to changes in gene expres-
sion and disturbances in the broad genome architecture 
and epigenomic landscape. Although many studies have 
focused on genes involved in aging and the related dis-
eases, the non-genetic regulation of aging is attracting 
increasing attention. The potential reversibility of these 
epigenetic changes, which occur as a sign of aging, offers 
exciting opportunities to change the trajectory of age-re-
lated diseases. Metformin and rapamycin are two FDA-
approved mTOR inhibitors exhibiting significant antican-
cer and antiaging properties beyond their current clinical 
use. However, each one faces problems with approval due 
to side effects. These two drugs are also discussed in the 
context of caloric restriction as mimetics (Ingram et al., 
2004). Caloric restriction is a well-known intervention 
to increase longevity in various species (Mattison et al., 
2017), but it may have limited practical value to humans 
(Phelan et al., 2005). Caloric restriction mimetics will 
theoretically have their beneficial effects without actually 
reducing calorie intake. The hallmarks of calorie restric-
tion are reduced circulating glucose and insulin levels, 
as well as responses to these reductions in nutrition and 
energy-sensitive networks, such as activation of AMP-
activated protein kinase (AMPK) and inhibition of mam-
malian rapamycin target (mTOR) (Zhavoronkov, 2015). 
The mTOR pathway is particularly important, being es-
sential for early development, but also potentially damag-
ing in later years if not suppressed, contributing to cellular 
aging and disease (Blagosklonny, 2015). Inhibition of the 
mTOR pathway slows conversion to aging (Blagosklonny, 
2015) and prolongs life expectancy in different species 
(Fabrizio et al., 2001; Vellai et al., 2003; Jia et al., 2004). 
Rapamycin and metformin, although different in clinical 
application, are both mTOR inhibitors and have multiple 
Table	3.	Effects	of	natural	compounds	on	epigenetic	and	antitumor	activity
Natural compounds Source Epigenetic/cellular effect Anticancer effect
Polyphenols: 
Resveratrol
Grapes, peanuts DNMT 3b inhibitor; decrease in RASSF-1α 
methylation with increasing circulating 
resveratrol; Suppress expression of the 
androgen receptor
Decreased risk of prostate cancer 
and breast cancer
Polyphenols: Genistein Soybeans Suppress expression of the androgen receptor 
(ER-β); inhibition of DMNT; demethylation of 
RARβ, p16 and MGMT promoters; demethylation 
of promoters of miR-29a and miR-1256
Inhibition of prostate cancer 
cell proliferation and invasion; 





Green tea Demethylation and/or suppressed 
methylation of TSG promoters (p15 and p16); 
inhibits HDAC activity.
Antioxidant activity; inhibition 
of angiogenesis; induction of 
apoptosis; inhibited invasive 
metastasis in a human pancreatic 
adenocarcinoma cell line
Isothiocyanates Cruciferous vegetables Interaction with xenobiotic compounds, 
smoking and consumption of cruciferous 
vegetables 
Anti-cancer effect: induced 
apoptosis and suppressed 
metastatic potential in lung cells. 
Folate Periconceptional folic 
acid supplementation; 
dark green leafy 
vegetables
Higher IGF2 methylation in offspring; higher 
hMLH1 promoter methylation 
Lower birth weight; association 
with colorectal cancer risk
α linoleic acid Flaxseed Decreased expression of COX 1 and COX 2 
when fed to male Fischer rats; Decreased 
COX 2 expression when fed to hens; Changed 
expression of genes associated with brain
Tumor incidence, multiplicity and 
size decreased; reduction in ovarian 
cancer incidence and severity; 
influence on brain development
Trans fatty acids Industrially processed 
foods and low levels in 
meat
DNA hypomethylation in the brains 
of offspring; histone modifications; 
hypomethylation at the SacII site in the ER gene 
in response to a diet high in omega 6 PUFA
During seven years of follow-up 
serum trans MUFA levels were 
associated with risk of invasive 
breast cancer
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anti-aging, anti-cancer, and cardiovascular benefits (Roth 
et al., 2016). Rapamycin (sirolimus) is an immunosup-
pressant used after kidney transplantation. It has been 
shown to reduce the risk of cancer after surgery in kidney 
transplant patients (Campistol et al., 2006; Yakupoglu et 
al., 2006; Garrick, 2007). Although the extent to which 
rapamycin’s anti-cancer properties underlie its anti-aging 
action and/or vice versa remains a matter of debate (Bla-
gosklonny 2015; Leontieva et al., 2015), it has also been 
reported or theorized to protect against a number of oth-
er aging-related diseases in humans with cardiovascular 
disease, osteoporosis, obesity, autoimmune diseases and 
arthritis, macular degeneration, diabetes, Alzheimer’s dis-
ease and Parkinson’s disease. While rapamycin interacts 
with various pathways associated with the transmission 
of nutritional signals, it acts primarily through direct in-
teraction of the mTOR 1 complex (mTORC1) (Roth et al., 
2016; Blagosklonny, 2017).
Through a combination of AMPK-dependent and 
-independent mechanisms (Zhou et al., 2001), metfor-
min affects a number of signaling pathways, including 
IGF-1 (Lib et al., 2011), Sirtuin 1 (SIRT1) (Arunacha-
lam et al., 2014; Zhong et al., 2015), and mTOR complex 
1 (mTORC1) (Howell et al., 2017), which contribute di-
rectly or indirectly to its clinical response and multiple 
antitumor effects. Taken together, rapamycin and met-
formin are promising candidates for increased longevity 
and health; however, concerns about side effects prevent 
their widespread use for this purpose. Although short-
term use of rapamycin is considered safe, side effects 
such as wound complications, oral ulcers, diarrhea, hy-
pokalemia, bronchopneumonia, proteinuria and with-
drawal syndrome are possible.
Metformin, although relatively safe, is poorly toler-
ated in one quarter to half of patients due to gastroin-
testinal side effects (Dujic et al., 2016). Given the urgent 
need for the prevention of aging and the prevention of 
diseases associated with it, it would be useful to consider 
natural alternatives such as nutraceuticals that would be 
safe enough for widespread use (Nasri et al., 2014).
The central question is whether epigenetic drugs 
will solve the problem of age-related diseases that accu-
mulate in the elderly. Thus, it will be worthwhile to test 




Other natural molecules have striking effects relevant for 
cancer research. For example, sulforaphane induces an-
ticancer activity and enhances xenobiotics metabolism, 
causing cell cycle arrest and apoptosis in human cancer 
cells (Clarke et al., 2008). Sulforaphane reduced the enzy-
matic activity of DNMT1 and DNMT3A and demethyl-
ated the first exon of the human TERT gene in human 
colon cancer cells and in breast cancer cells (Traka et al., 
2005; Meeran et al., 2010). It was found that sulforaphane 
and 3,3’-diindolylmethane induced the reactivation of tu-
mor suppressor genes suppressed in cancer cells by DNA 
methylation (Kaufman-Szymczyk et al., 2015). Also, it has 
been shown that both sulforaphane and 3,3’-diindolyl-
methane could reduce the expression of DNA methyl-
transferases, leading to general hypomethylation of pro-
moters in androgen-dependent and -independent human 
prostate cancer cells (Wong et al., 2014). Interestingly, 
sulforaphane and 3,3’-diindolylmethane have common 
gene targets that are actively involved in the progression 
of the same type of cancer (Wong et al., 2014). Phenethy-
lisothiocyanate was found to inhibit growth and induce 
apoptosis in cancer cells (Cheung et al., 2010). Human 
prostate cancer cells exposed to phenethylisothiocyanate 
demonstrated demethylation of the GSTP1  gene pro-
moter, reduced HDAC activity and activated acetylation 
and methylation of histones at specific loci (Wang et al., 
2007). Indole-3-carbinol is purified from the representa-
tives of the cruciferous family (Brassicaceae), including 
broccoli, cabbage, cauliflower, mustard, and radish. In the 
acidic environment of the stomach, indole-3-carbinol is 
converted into diindolylmethane. Both indole-3-carbinol 
and diindolylmethane induced apoptosis in various can-
cer cell lines by modulation of nuclear receptor mediated 
signals (Rahman et al., 2006; Banerjee et al., 2011; Chen 
et al., 2012; Safa et al., 2015). Indole-3-carbinol inhibits 
NF-κB activity and stimulates the p53-dependent path-
way and its downstream target genes and activates apop-
totic protease factor (APAF) –1  in acute lymphoblastic 
leukemia cells (MDA-MB-231 and MCF-7) by suppress-
ing STAT3 and NF-κB signaling (Chung et al., 2015). Ku-
kurbitatsin B from Hemsleya endecaphylla reduced tumor 
cell proliferation and induced their apoptosis through 
modulating the STAT3 pathway in the human lung can-
cer cell line (Zhang et al., 2014). It has been reported that 
a compound from Eurycoma longifolia, eurycomanone, 
inhibited the viability and proliferation of Jurkat and 
K562 cells but didn’t have such an effect on benign cells 
(Orlikova et al., 2013; Hajjouli et al., 2014). Strikingly, 
eurycomanone repressed the NF-KB signaling by inhibit-
ing IkB phosphorylation and signaling by the mitogen-
activated protein kinase (Orlikova et al., 2013; Hajjouli et 
al., 2014). Aaptamine from the marine sponge Aaptos sp. 
was shown to reduce the proliferation of various human 
cancer cell types by modulating AP-1, NF-κB, and p53-
dependent transcription activity (Dyshlovoy et al., 2014). 
Codenomicon, a sesquiterpene lactone from Chloranthus 
henryi, inhibits cancer cell invasion, migration, and me-
tastasis of breast cancer cells, inhibiting RUNX2  tran-
scriptional activity (Wang W et al., 2014). Kirstin from 
Uncaria rhynchophylla is an anti-metastatic phytochemi-
cal that inhibits the invasion of breast cancer cells through 









targeting of NF-κB factor for activation (Lou et al., 2014). 
Bergamottin is a natural furanocoumarin from grapefruit 
juice that promotes the apoptosis of myeloma cells via in-
hibiting the STAT3 signaling (Kim et al., 2014). Annona 
muricata extract induced cell cycle arrest and apoptosis 
in A549 cells by activating mitochondrial mediated sig-
naling and suppressing nuclear translocation of NF-κB 
(Moghadamtousi et al., 2014).
Ethanol extracts of Piriformospora indica roots sig-
nificantly increased the expression of TP53  protein in 
human nasopharyngeal carcinoma cells in a time- and 
dose-dependent manner (Kao et al., 2015). It has been 
further shown that grifolin from Albatrellus confluens 
fungus induced cell cycle arrest in various human cancer 
cells by targeting extracellular signal-regulated kinase 
1  or by activating the death-associated protein kinase 
(DAPK) –1  via regulating TP53  transcription (Luo et 
al., 2015). Chalcons are natural compounds from vari-
ous spices, tea, beers, fruits and vegetables, which can 
modulate transcription factors employed by key cancer 
pathways, including TP53, NF-KB, STAT3, AP-1, NRF2, 
and Wnt (Jandial et al., 2014). It was found that the herb-
al alkaloid carbazole mahanine activates TP53 protein, 
which leads to the accumulation of reactive oxygen spe-
cies in the nucleus. It also affects PTEN and its interac-
tion with TP53 / TP73 proteins in colorectal cancer cells, 
and it was also shown to inhibit STAT3  expression in 
cervical cancer cells (Das et al., 2014).
Dehydroleucodine from Gynoxys verrucosa (Ecua-
dor) caused cell cycle arrest, apoptosis, and DNA dam-
age in human astrocytoma cells (Bailón-Moscoso et al., 
2015). Enhanced expression of the cyclin-dependent ki-
nase inhibitor (CDKN1A) and protein BAX, as well as the 
phosphorylation of proteins TP53, TP73, and γ-H2AX 
in cancer cells exposed to dihydrocodeine resulted in cell 
death (Bailón-Moscoso et al., 2015). Z-ligustilide from 
Radix Angelicae Sinensis restored Nrf2 gene expression 
as well as Nrf2 downstream genes (e.g., HO1, NQO1 and 
UGT1A1) in breast cancer cells (Su et al., 2013). Treatment 
with Z-ligustilide inhibited DNMT activity in vitro and re-
duced the level of methylation of the Nrf2 promoter region. 
This study demonstrated that Nrf2 expression is likely to 
be epigenetically controlled, and this control was affected 
by natural compounds, allowing the prevention of carcino-
genesis in the TRAMP mouse prostate cancer model (Su et 
al., 2013). Trichostatin A from actinomycete Streptomyces 
hygroscopicus is a potent inhibitor of pan-HDAC activity 
and has been found to induce apoptosis by increasing BAX 
and CASP3 protein levels, also reducing the telomerase ex-
pression (TERT) (Woo et al., 2007). It was discovered that 
depsipeptide FK228 from Chromobacterium violaceum 
specifically inhibited class I HDACs, inducing apoptosis 
of leukemic human cells (Furumai et al., 2002; Konstan-
tinopoulos et al., 2006). In addition, FK228 induced the 
autophagy pathway and translocation of the apoptosis-in-
duced factor (AIF) from mitochondria to the nucleus. This 
compound was approved by the FDA for the treatment of 
cutaneous T-cell lymphomas as Istodax.
Our recent study identified three endemic plants 
from Mauritius affecting the cell cycle of human oesoph-
ageal squamous carcinoma cells (Rummun et al., 2019). 
Treatment with extracts of these plant leaves induced 
AMPK pathway activation (Rummun et al., 2019). More 
research is necessary to identify and test the effector 
molecules in these extracts, as well as their exact mech-
anisms of action. A promising path to new anticancer 
therapies is building cell-based systems for phenotypic 
screening of natural extracts made from various species, 
e.g., ones used in traditional medicine. For example, 
such phenotype-based models make it possible to iden-
tify small molecules affecting HDACi and DNMTi and 
other major epigenetic regulators.
Concluding	remarks
Reversibility of epigenetic changes could open up excit-
ing opportunities for age-related diseases. An important 
goal for the future will be the identification of epigenetic 
drugs to reverse the epigenetic changes which occur as a 
sign of aging and aging diseases such as cancer. Several 
specific compounds have been developed which target 
enzymes responsible for epigenetic changes and are in 
clinical trials for testing for some age-related diseases, 
including cancer. A key challenge in this approach will 
be to develop additional drugs that specifically affect 
epigenetic pathways and test existing drugs on well-
studied animal models.
Overall it is now well established that a variety of nat-
ural compounds can be used to modulate epigenetic regu-
latory mechanisms in tumor cells, enhancing or inhibit-
ing epigenetic regulators to change gene regulation, and 
therefore control the expression of a large number of pro-
teins and their properties. As a result, such epigenetic in-
terference may induce cell cycle arrest, cell differentiation 
or cell death via apoptosis, necrosis, autophagy, or mitotic 
catastrophe in tumor cells as well as shape the microenvi-
ronment of the tumor (Yu et al., 2010). However, further 
in-depth studies are needed to determine the contribution 
of epigenetic changes caused by natural compounds in 
various human cancers. A better understanding of epigen-
etic targets and pathways altered by natural compounds is 
needed to develop new strategies in chemoprevention, in-
cluding their combinations with chemotherapy currently 
in use, as well as their anti-aging applications.
References
Abdelfatah, E., Kerner, Z., Nanda, N., and Ahuja, N. 2016. Epigen-
etic therapy in gastrointestinal cancer: the right combina-
tion. Therapeutic Advances in Gastroenterology 9(4):560–
579. https://doi.org/10.1177/1756283X16644247
324 BIOLOGICAL  COMMUNICATIONS,  vol. 65,  issue 4,  October–December,  2020 | https://doi.org/10.21638/spbu03.2020.405
Adam, S. and Polo, S. E. 2014. Blurring the line between 
the DNA damage response and transcription: the im-
portance of chromatin dynamics. Experimental Cell 
Research 329(1):148–53. https://doi.org/10.1016/j.yex-
cr.2014.07.017
Ahmad, K. and Henikoff, S. 2002. The histone variant 
H3.3 marks active chromatin by replication-independent 
nucleosome assembly. Molecular Cell 9(6):1191–200. 
https://doi.org/10.1016/S1097-2765(02)00542-7
AlQathama, A. and Prieto, J. M. 2015. Natural compounds 
with therapeutic potential in melanoma metastasis. 
Natural Product Reports 32(8):1170–1182. https://doi.
org/10.1039/c4np00130c
Andreoli, V., Gehrau, R. C., and Bocco, J. L. 2010. Biology of 
Krüppel-like factor 6  transcriptional regulator in cell 
life and death. IUBMB Life 62(12):896–905. https://doi.
org/10.1002/iub.396
Azevedo, C. and Saiardi, A. 2016. Why always lysine? The 
ongoing tale of one of the most modified amino acids. 
Advances in Biological Regulation 60:144–150. https://doi.
org/10.1016/j.jbior.2015.09.008
Bailon-Moscoso, N., Cevallos-Solorzano, G., Romero-Bena-
vides, J. C., and Orellana, M. 2017. Natural compounds as 
modulators of cell cycle arrest: application for antican-
cer chemotherapies. Current Genomics 18(2):106–131. 
https://doi.org/10.2174/1389202917666160808125645
Bailón-Moscoso, N., González-Arévalo, G., Velásquez-Rojas, 
G., Malagon, O., Vidari, G., Zentella-Dehesa, A., Ratovi-
tski, E. A., and Ostrosky-Wegman, P. 2015. Phytometab-
olite dehydroleucodine induces cell cycle arrest, apop-
tosis, and DNA damage in human astrocytoma cells 
through p73/p53  regulation. PLoS One 10(8):e0136527. 
https://doi.org/10.1371/journal.pone.0136527
Bajpe, P. K., Prahallad, A., Horlings, H., Nagtegaal, I., Beijer-
sbergen, R., and Bernards, R. 2014. A chromatin modi-
fier genetic screen identifies SIRT2  as a modulator of 
response to targeted therapies through the regulation 
of MEK kinase activity. Oncogene 34(4):531–536. https://
doi.org/10.1038/onc.2013.588
Banerjee, S., Kong, D., Wang, Z., Bao, B., Hillman, G. G., and 
Sarkar, F. H. 2011. Attenuation of multi-targeted prolif-
eration-linked signaling by 3,3’-diindolylmethane (DIM): 
from bench to clinic. Mutation Research 728(1–2):47–66. 
https://doi.org/10.1016/j.mrrev.2011.06.001
Bannister, A. J., Eckerman, P., Partridge, J. F., Miska, E. A., 
Thomas, J. O., Allshire, R. C., and Kouzarides, T. 2001. 
Selective recognition of methylated lysine 9 on histone 
H3 by HP1 chromo domain. Nature 410:120–124. https://
doi.org/10.1038/35065138
Berletch, J. B., Liu, C., Love, W. K., Andrews, L. G., Katiyar, S. K., 
and Tollefsbol, T. O. 2008 Epigenetic and genetic mecha-
nisms contribute to telomerase inhibition by EGCG. Jour-
nal of Cellular Biochemistry 103(2):509–519. https://doi.
org/10.1002/jcb.21417
Bhanot, A., Sharma, R., and Malleshappa, N. 2011. Natural 
sources as potential anti-cancer agents: A review. Inter-
national Journal of Phytomedicine 3:9–26.
Bishop, K. and Ferguson, L. 2015. The interaction between 
epigenetics, nutrition and the development of cancer. 
Nutrients 7:922–947. https://doi.org/10.3390/nu7020922
Bojang, P. Jr. and Ramos, K. S. 2014.The promise and fail-
ures of epigenetic therapies for cancer treatment. 
Cancer Treatment Reviews 40(1):153–169. https://doi.
org/10.1016/j.ctrv.2013.05.009
Bora-Tatar, G., Dayangac-Erden, D., Demir, A. S., Dalkara, S., 
Yelekci, K., and Erdem-Yurter, H. 2009. Molecular modi-
fications on carboxylic acid derivatives as potent histone 
deacetylase inhibitors: Activity and docking studies. Bio-
organic & Medicinal Chemistry 17:5219–5228. https://doi.
org/10.1016/j.bmc.2009.05.042
Brunet, A. and Berger, S. L. 2014. Epigenetics of aging and ag-
ing-related disease. The Journals of Gerontology. Series A, 
Biological Sciences and Medical Sciences 69(S1):S17–S20. 
https://doi.org/10.1093/gerona/glu042
Buscaino, A., Allshire, R., and Pidoux, A. 2010. Review of 
the building the centromere: home sweet home or a 
nomadic existence? Current Opinion in Genetics & De-
velopment 20(2):118–126. https://doi.org/10.1016/j.
gde.2010.01.006
Chen, C. C., Chen, H. L., Hsieh, C. W., Yang, Y. L., and Wung, B. S. 
2011. Upregulation of NF-E2-related factor-2-dependent 
glutathione by carnosol provokes a cytoprotective re-
sponse and enhances cell survival. Acta Pharmacologica 
Sinica 32(1):62–69. https://doi.org/10.1038/aps.2010.181
Chen, D., Banerjee, S., Cui, Q. C., Kong, D., Sarkar, F. H., and 
Dou, Q. P. 2012. Activation of AMP-activated protein ki-
nase by 3,3’-Diindolylmethane (DIM) is associated with 
human prostate cancer cell death in vitro and in vivo. 
PLoS One. 7(10):e47186. https://doi.org/10.1371/journal.
pone.0047186
Chen, H. P., Zhao, Y. T., and Zhao, T. C. 2015. Histone deacety-
lases and mechanisms of regulation of gene expression. 
Critical Reviews in Oncogenesis 20(1–2):35–47. https://doi.
org/10.1615/CritRevOncog.2015012997
Chen, Q., Ganapathy, S., Singh, K. P., Shankar, S., and Srivas-
tava, R. K. 2010. Resveratrol induces growth arrest and 
apoptosis through activation of FOXO transcription fac-
tors in prostate cancer cells. PLoS One 5(12):e15288. 
https://doi.org/10.1371/journal.pone.0015288
Chen, Y., Shu, W., Chen, W., Wu, Q., Liu, H., and Cui, G. 2007. 
Curcumin, both histone deacetylase and p300/CBP-
specific inhibitor, represses the activity of nuclear fac-
tor kappa B and Notch 1  in Raji cells. Basic & Clinical 
Pharmacology & Toxicology 101:427–433. https://doi.
org/10.1111/j.1742-7843.2007.00142.x
Cherblanc, F. L., Davidson, R. W., Di Fruscia, P., Srimongkol-
pithak, N., and Fuchter M. J. 2013. Perspectives on natu-
ral compound epigenetic modulators in chemical biolo-
gy and medicine. Natural Product Reports 30(5):605–624. 
https://doi.org/10.1039/c3np20097c
Cheung, K. L. and Kong, A. N. 2010. Molecular targets of di-
etary phenethyl isothiocyanate and sulforaphane for 
cancer chemoprevention. The AAPS Journal 12(1):87–97. 
https://doi.org/10.1208/s12248-009-9162-8
Choi, J. H., Kwon, H. J., Yoon, B. I., Kim, J. H., Han, S. U., Joo, H. J., 
and Kim, D. Y. 2001. Expression profile of histone 
deacetylase 1  in gastric cancer tissues. Japanese Jour-
nal of Cancer Research 92(12):1300–1304. https://doi.
org/10.1111/j.1349-7006.2001.tb02153.x
Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., and Mann, 
M. 2014. The growing landscape of lysine acetylation 
links metabolism and cell signalling. Nature Reviews. Mo-
lecular Cell Biology (8):536–550. https://doi.org/10.1038/
nrm3841
Chung, S. S. and Vadgama, J. V. 2015. Curcumin and epigal-
locatechin gallate inhibit the cancer stem cell phenotype 
via down-regulation of STAT3-NFκB signaling. Anticancer 
Research 35(1):39–46.
Clarke, J. D., Dashwood, R. H., and Ho, E. 2008. Multi-tar-
geted prevention of cancer by sulforaphane. Cancer 
Letters 269(2):291–304. https://doi.org/10.1016/j.can-
let.2008.04.018
Cordero-Herrera, I., Martín, M. A., Bravo, L., Goya, L., and 
Ramos, S. 2013. Epicatechin gallate induces cell death 
via p53  activation and stimulation of p38  and JNK in 
human colon cancer SW480  cells. Nutrition and Cancer 











Darnell, J. E. 2002. Trascription factors as targets for cancer 
therapy. Nature Reviews. Cancer 2(10):740–749. https://
doi.org/10.1038/nrc906
Das, R., Bhattacharya, K., Samanta, S. K., Pal, B. C., and Man-
dal, C. 2014. Improved chemosensitivity in cervical can-
cer to cisplatin: synergistic activity of mahanine through 
STAT3 inhibition. Cancer Letters 351(1):81–90. https://doi.
org/10.1016/j.canlet.2014.05.005
Das, R., Bhattacharya, K., Sarkar, S., Samanta, S. K., Pal, B. C., 
and Mandal, C. 2014. Mahanine synergistically enhances 
cytotoxicity of 5-fluorouracil through ROS-mediated acti-
vation of PTEN and p53/p73 in colon carcinoma. Apopto-
sis 19(1):149–164. https://doi.org/10.1007/s10495-013-
0907-6
Dhar, S., Kumar, A., Li, K., Tzivion, G., and Levenson, A. S. 2015. 
Resveratrol regulates PTEN/Akt pathway through inhibi-
tion of MTA1/HDAC unit of the NuRD complex in pros-
tate cancer. Biochimica et Biophysica Acta 1853(2):265–
275. https://doi.org/10.1016/j.bbamcr.2014.11.004
Di, C., Sun, C., Li, H., Si, J., Zhang, H., Han, L., Zhao, Q., Liu, Y., 
Liu, B., Miao, G., Gan, L., and Liu, Y. 2015. Diallyl disul-
fide enhances carbon ion beams-induced apoptotic cell 
death in cervical cancer cells through regulating TAp73 /
ΔNp73. Cell Cycle 14(23):3725–3733. https://doi.org/10.1
080/15384101.2015.1104438
Ding, D. F., Li, X. F., Xu, H., Wang, Z., Liang, Q. Q., Li, C. G., and 
Wang, Y. J. 2013. Mechanism of resveratrol on the pro-
motion of induced pluripotent stem cells. Journal of Inte-
grative Medicine 11(6):389–396. https://doi.org/10.3736/
jintegrmed2013039
Dokmanovic, M., Clarke, C., and Marks, P. A. 2007. Histone 
deacetylase inhibitors: overview and perspectives. 
Molecular Cancer Research 5(10):981–989. https://doi.
org/10.1158/1541-7786.MCR-07-0324
Dou, Q. P. 2009. Molecular mechanisms of green tea poly-
phenols. Nutrition and Cancer 61(6):827–835. https://doi.
org/10.1080/01635580903285049
Dyshlovoy, S. A., Fedorov, S. N., Shubina, L. K., Kuzmich, A. S., 
Bokemeyer, C., Keller-von Amsberg, G., and Honeck-
er,  F. 2014. Aaptamines from the marine sponge Aap-
tos sp. display anticancer activities in human cancer 
cell lines and modulate AP1-, NF-κB-, and p53-depen-
dent transcriptional activity in mouse JB6  Cl41  cells. 
BioMed Research International 469309. https://doi.
org/10.1155/2014/469309
Easwaran, H., Tsai, H. C., and Baylin, S. B. 2014. Cancer epi-
genetics: tumor heterogeneity, plasticity of stem-like 
states, and drug resistance. Molecular Cell 54(5):716–727. 
https://doi.org/10.1016/j.molcel.2014.05.015
Fang, M., Chen, D., and Yang, C. S. 2007. Dietary polyphenols 
may affect DNA methylation. The Journal of Nutrition 
223S–228S. https://doi.org/10.1093/jn/137.1.223S
Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., 
Holcombe, R. F., et al. 2015. Sustained proliferation in 
cancer: Mechanisms and novel therapeutic targets. 
Seminars in Cancer Biology 35:S25–S54. https://doi.
org/10.1016/j.semcancer.2015.02.006
Feng, B., Ng, J. H., Heng, J. C., and Ng, H. H. 2009. Molecules that 
promote or enhance reprogramming of somatic cells to 
induced pluripotent stem cells. Cell Stem Cell 4(4):301–
312. https://doi.org/10.1016/j.stem.2009.03.005
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., 
Espada, J., Schotta, G., et al. 2005. Loss of acetylation 
at Lys16  and trimethylation at Lys20  of histone H4  is 
a common hallmark of human cancer. Nature Genetics 
37(4):391–400. https://doi.org/10.1038/ng1531
Fujiwara, Y., Komohara, Y., Ikeda, T., and Takeya, M. 2011. 
Corosolic acid inhibits glioblastoma cell proliferation by 
suppressing the activation of signal transducer and ac-
tivator of transcription-3 and nuclear factor-kappa B in 
tumor cells and tumor-associated macrophages. Cancer 
Science 102(1):206–211. https://doi.org/10.1111/j.1349-
7006.2010.01772.x
Furumai, R., Matsuyama, A., Kobashi, N., Lee, K. H., Nishi-
yama, M., Nakajima, H., Tanaka, A., Komatsu, Y., Nishi-
no, N., Yoshida, M., and Horinouchi, S. 2002. FK228 (dep-
sipeptide) as a natural prodrug that inhibits class I his-
tone deacetylases. Cancer Research 62(17):4916–4921.
Ganapathy, S., Chen, Q., Singh, K. P., Shankar, S., and Srivas-
tava, R. K. 2010. Resveratrol enhances antitumor activity 
of TRAIL in prostate cancer xenografts through activa-
tion of FOXO transcription factor. PLoS One 5(12):e15627. 
https://doi.org/10.1371/journal.pone.0015627
Gao, Z., Xu, Z., Hung, M. S., Lin, Y. C., Wang, T., Gong, M., Zhi, X., 
Jablon, D. M., and You, L. 2009. Promoter demethylation 
of WIF-1  by epigallocatechin-3-gallate in lung cancer 
cells. Anticancer Research 29(6):2025–2030.
Gerhauser, C. 2013. Cancer chemoprevention and nutri-
epigenetics: state of the art and future challenges. 
Topics in Current Chemistry 329:73–132. https://doi.
org/10.1007/128_2012_360
Gibbons, R. J. 2005. Histone modifying and chromatin re-
modelling enzymes in cancer and dysplastic syndromes. 
Human Molecular Genetics 14:R85–92. https://doi.
org/10.1093/hmg/ddi106
Gillespie, S., Borrow, J., Zhang, X. D., and Hersey, P. 2006. Bim 
plays a crucial role in synergistic induction of apoptosis 
by the histone deacetylase inhibitor SBHA and TRAIL in 
melanoma cells. Apoptosis 11:2251–2265. https://doi.
org/10.1007/s10495-006-0283-6
Grewal, S. I. and Jia, S. 2007. Heterochromatin revisited. Nature 
Reviews. Genetics 8(1):35–46. https://doi.org/10.1038/
nrg2008
Guo, H., Xu, Y., and Fu, Q. 2015. Curcumin inhibits growth of 
prostate carcinoma via miR-208-mediated CDKN1A ac-
tivation. Tumour Biology 36(11):8511–8517. https://doi.
org/10.1007/s13277-015-3592-y
Haack, M., Löwinger, M., Lippmann, D., Kipp, A., Pagnotta, E., 
Iori, R., Monien, B. H., Glatt, H., Brauer, M. N., Wessjo-
hann, L. A., and Brigelius-Flohé, R. 2010. Breakdown 
compounds of neoglucobrassicin inhibit activation of 
Nrf2  target genes mediated by myrosinase-derived glu-
coraphanin hydrolysis compounds. Biological Chemistry 
391(11):1281–1293. https://doi.org/10.1515/BC.2010.134
Hajjouli, S., Chateauvieux, S., Teiten, M. H., Orlikova, B., Schum-
acher, M., Dicato, M., Choo, C. Y., and Diederich, M. 2014. 
Eurycomanone and eurycomanol from Eurycoma longi-
folia Jack as regulators of signaling pathways involved 
in proliferation, cell death and inflammation. Molecules 
19(9):14649–14666. https://doi.org/10.3390/mole-
cules190914649
Halkidou, K., Gaughan, L., Cook, S, Leung, H. Y., Neal, D. E., 
and Robson, C. N. 2004. Upregulation and nuclear re-
cruitment of HDAC1  in hormone refractory prostate 
cancer. Prostate 59(2):177–189. https://doi.org/10.1002/
pros.20022
Hassan, M. Q., Tye, C. E., Stein, G. S., and Lian, J. B. 2015. Non-
coding RNAs: Epigenetic regulators of bone develop-
ment and homeostasis. Bone 81:746–756. https://doi.
org/10.1016/j.bone.2015.05.026
Henning, S. M., Wang, P., Carpenter, C. L., and Heber, D. 2013. 
Epigenetic effects of green tea polyphenols in cancer. 
Epigenomics 5(6):729–741. https://doi.org/10.2217/
epi.13.57
326 BIOLOGICAL  COMMUNICATIONS,  vol. 65,  issue 4,  October–December,  2020 | https://doi.org/10.21638/spbu03.2020.405
Henning, S. M., Wang, P., Said, J., Magyar, C., Castor, B., 
Doan, N., Tosity, C., Moro, A., Gao, K., Li, L., and Heber, D. 
2012. Polyphenols in brewed green tea inhibit prostate 
tumor xenograft growth by localizing to the tumor and 
decreasing oxidative stress and angiogenesis The Jour-
nal of Nutritional Biochemistry. 23(11):1537–1542. https://
doi.org/10.1016/j.jnutbio.2011.10.007
Ho, E., Beaver, L. M., Williams, D. E., and Dashwood, R. H. 2011. 
Dietary factors and epigenetic regulation for prostate 
cancer prevention. Advances in Nutrition (Bethesda, Md.) 
2(6):497–510. https://doi.org/10.3945/an.111.001032
Hong, K. J., Wu, D. C., Cheng, K. H., Chen, L. T., and Hung, W. C. 
2014. RECK inhibits stemness gene expression and tu-
morigenicity of gastric cancer cells by suppressing AD-
AM-mediated Notch1 activation. Journal of Cellular Physi-
ology 229(2):191–201. https://doi.org/10.1002/jcp.24434
Huang, J., Plass, C., and Gerhauser, C. 2011. Cancer che-
moprevention by targeting the epigenome. Cur-
rent Drug Targets 12(13):1925–1956. https://doi.
org/10.2174/138945011798184155
Huang, M. T., Newmark, H. L., and Frenkel, K. 1997. Inhibi-
tory effects of curcumin on tumorigenesis in mice. 
Journal of Cellular Biochemistry 27:26–34. https://doi.
org/10.1002/(SICI)1097-4644(1997)27+%3C26::AID-
JCB7%3E3.0.CO;2-3
Huisinga, K. L., Brower-Toland, B., and Elgin, S. C. 2006. The 
contradictory definitions of heterochromatin: transcrip-
tion and silencing. Chromosoma 115(2):110–122. https://
doi.org/10.1007/s00412-006-0052-x
Jandial, D. D., Blair, C. A., Zhang, S., Krill, L. S., Zhang, Y. B., and 
Zi, X. 2014. Molecular targeted approaches to cancer 
therapy and prevention using chalcones. Current Cancer 
Drug Targets 14(2):181–200. https://doi.org/10.2174/156
8009614666140122160515
Jenuwein, T. and Allis, C. D. 2001. Translating the histone code. 
Science 293(5532):1074–1080. https://doi.org/10.1126/
science.1063127
Jia, Y. and Guo, M. 2013. Epigenetic changes in colorectal can-
cer. Chinese Journal of Cancer 32(1):21–30. https://doi.
org/10.5732/cjc.011.10245
Jones, P. A. and Baylin, S. B. 2007. The epigenomics of can-
cer. Cell 128(4):683–692. https://doi.org/10.1016/j.
cell.2007.01.029
Kai, L., Samuel, S. K., and Levenson, A. S. 2010. Resveratrol en-
hances p53 acetylation and apoptosis in prostate cancer 
by inhibiting MTA1/NuRD complex. International Journal 
of Cancer 126(7):1538–1548. https://doi.org/10.1002/
ijc.24928
Kao, C. L., Cho, J., Lee, Y. Z., Cheng, Y. B., Chien, C. Y., 
Hwang,  C. F., Hong, Y. R., Tseng, C. N., and Cho, C. L. 
2015. Ethanolic extracts of Pluchea indica induce apop-
tosis and antiproliferation effects in human nasopha-
ryngeal carcinoma cells. Molecules 20(6):11508–11523. 
https://doi.org/10.3390/molecules200611508
Kato, K., Long, N. K., Makita, H., Toida, M., Yamashita, T., 
Hatakeyama, D., Hara, A., Mori, H., and Shibata, T. 2008. 
Effects of green tea polyphenol on methylation status 
of RECK gene and cancer cell invasion in oral squamous 
cell carcinoma cells. British Journal of Cancer 99(4):647–
654. https://doi.org/10.1038/sj.bjc.6604521
Khoury, G. A., Baliban, R. C., and Floudas, C. A. 2011. Pro-
teome-wide post-translational modification statistics: 
frequency analysis and curation of the swiss-prot da-
tabase. Scientific Reports 1:90. https://doi.org/10.1038/
srep00090
Kikuno, N., Shiina, H., Urakami, S., Kawamoto, K., Hirata, H., 
Tanaka, Y., Majid, S., Igawa, M., and Dahiya, R. 2008. Me-
diated histone acetylation and demethylation activates 
tumor suppressor genes in prostate cancer cells. Inter-
national Journal of Cancer 123(3):552–560. https://doi.
org/10.1002/ijc.23590
Kim, H. J. and Bae, S. C. 2011. Histone deacetylase inhibitors: 
molecular mechanisms of action and clinical trials as 
anti-cancer drugs. American Journal of Transational Re-
search 3(2):166–179.
Kim, S. M., Lee, J. H., Sethi, G., Kim, C., Baek, S. H., Nam, D., 
Chung, W. S., Kim, S. H., Shim, B. S., and Ahn, K. S. 2014. 
Bergamottin, a natural furanocoumarin obtained from 
grapefruit juice induces chemosensitization and apop-
tosis through the inhibition of STAT3 signaling pathway 
in tumor cells. Cancer Letters 354(1):153–163. https://doi.
org/10.1016/j.canlet.2014.08.002
Kim, Y. Z. 2014. Altered histone modifications in gliomas. 
Brain Tumor Research and Treatment 2(1):7–21. https://
doi.org/10.14791/btrt.2014.2.1.7
Kong, D., Heath, E., Chen, W., Cher, M. L., Powell, I., Hei-
lbrun,  L., Li, Y., Ali, S., Sethi, S., Hassan, O., Hwang, C., 
Gupta, N., Chitale, D., Sakr, W. A., Menon, M., and 
Sarkar, F. H. 2012. Loss of let-7  up-regulates EZH2  in 
prostate cancer consistent with the acquisition of can-
cer stem cell signatures that are attenuated by BR-DIM. 
PLoS One 7(3):e33729. https://doi.org/10.1371/journal.
pone.0033729
Konstantinopoulos, P. A., Vandoros, G. P., and Papavassil-
iou, A. G. 2006. FK228 (depsipeptide): a HDAC inhibitor 
with pleiotropic antitumor activities. Cancer Chemo-
therapy and Pharmacology 58(5):711–715. https://doi.
org/10.1007/s00280-005-0182-5
Krishnan, M., Singh, A. B., Smith, J. J., Sharma, A., Chen, X., 
Eschrich, S., Yeatman, T. J., Beauchamp, R. D., and Dha-
wan,  P. 2010. HDAC inhibitors regulate claudin-1  ex-
pression in colon cancer cells through modulation of 
mRNA stability. Oncogene 29(2):305–312. https://doi.
org/10.1038/onc.2009.324
Lee, E. Y. and Muller, W. J. 2010. Oncogenes and tumor sup-
pressor genes. Cold Spring Harbor Perspectives in Biol-
ogy 2(10):a003236. https://doi.org/10.1101/cshperspect.
a003236
Lee, J. S. 2007. Functional link between DNA damage respons-
es and transcriptional regulation by ATM in response to 
a histone deacetylase inhibitor TSA. Cancer Research and 
Treatment: Official Journal of Korean Cancer Association 
39:116–124. https://doi.org/10.4143/crt.2007.39.3.116
Lee, T. I. and Young, R. A. 2013. Transcriptional regulation 
and its misregulation in disease. Cell 152(6):1237–1251. 
https://doi.org/10.1016/j.cell.2013.02.014
Lee, W. J., Shim, J. Y., and Zhu, B. T. 2005. Mechanisms for the 
inhibition of DNA methyltransferases by tea catechins 
and bioflavonoids. Molecular Pharmacology 68(4):1018–
1030. https://doi.org/10.1124/mol.104.008367
Levenson, A. S., Kumar, A., and Zhang, X. 2014. MTA family 
of proteins in prostate cancer: biology, significance, and 
therapeutic opportunities. Cancer Metastasis Reviews 
33(4):929–942. https://doi.org/10.1007/s10555-014-
9519-z
Li, B., Zhao, J., Wang, C. Z., Searle, J., He, T. C., Yuan, C. S., 
and Du, W. 2011. Ginsenoside Rh2  induces apoptosis 
and paraptosis-like cell death in colorectal cancer cells 
through activation of p53. Cancer Letters 301(2):185–192. 
https://doi.org/10.1016/j.canlet.2010.11.015
Li, K., Dias, S. J., Rimando, A. M., Dhar, S., Mizuno, C. S., Pen-
man, A. D., Lewin, J. R., and Levenson, A. S. 2013. Pteros-
tilbene acts through metastasis-associated protein 
1  to inhibit tumor growth, progression and metastasis 
in prostate cancer. PLoS One 8(3):e57542. https://doi.
org/10.1371/journal.pone.0057542









Li, Y., Kong, D., Wang, Z., and Sarkar, F. H. 2010. Regulation of 
microRNAs by natural agents: an emerging field in che-
moprevention and chemotherapy research. Pharmaceu-
tical Research 27(6):1027–1041. https://doi.org/10.1007/
s11095-010-0105-y
Lin, J. K. 2007. Molecular targets of curcumin. Advances in Ex-
perimental Medicine and Biology 595:227–243. https://
doi.org/10.1007/978-0-387-46401-5_10
Link, A., Balaguer, F., and Goel, A. 2010.Cancer chemopre-
vention by dietary polyphenols: promising role for epi-
genetics. Biochemical Pharmacology 80(12):1771–1792. 
https://doi.org/10.1016/j.bcp.2010.06.036
Liu, H. L., Chen, Y., Cui, G. H., and Zhou, J. F. 2005. Curcumin, 
a potent anti-tumor reagent, is a novel histone deacety-
lase inhibitor regulating B-NHL cell line Raji proliferation. 
Acta Pharmacologica Sinica 26(5):603–609. https://doi.
org/10.1111/j.1745-7254.2005.00081.x
Liu, J. D., Chen, S. H., Lin, C. L., Tsai, S. H., and Liang, Y. C. 2001. 
Inhibition of melanoma growth and metastasis by com-
bination with (-)-epigallocatechin-3-gallate and dacarba-
zine in mice. Journal of Cellular Biochemistry 83(4):631–
642. https://doi.org/10.1002/jcb.1261
Liu, Z., Xie, Z., Jones, W., Pavlovicz, R. E., Liu, S., Yu, J., Li, P. K., 
Lin, J., Fuchs, J. R., Marcucci, G., Li, C., and Chan, K. K. 
2009. Curcumin is a potent DNA hypomethylation agent. 
Bioorganic & Medicinal Chemistry Letters 19(3):706–709. 
https://doi.org/10.1016/j.bmcl.2008.12.041
Lizcano, F. and Garcia, J. 2012. Epigenetic control and can-
cer: the potential of histone demethylases as therapeu-
tic targets. Pharmaceuticals 5(9):963–999. https://doi.
org/10.3390/ph5090963
Losson, H., Schnekenburger, M., Dicato, M., and Diederich, M. 
2016. Natural compound histone deacetylase inhibi-
tors (HDACi): Synergy with inflammatory signaling path-
way modulators and clinical applications in cancer. 
Molecules 21(11):1608. https://doi.org/10.3390/mole-
cules21111608
Lou, C., Takahashi, K., Irimura, T., Saiki, I., and Hayakawa, Y. 
2014. Identification of Hirsutine as an anti-metastatic 
phytochemical by targeting NF-κB activation. Interna-
tional Journal of Oncology 45(5):2085–2091. https://doi.
org/10.3892/ijo.2014.2624
Lu, Q. Y., Jin, Y. S., Zhang, Z. F., Le, A. D., Heber, D., Li, F. P., 
Dubinett, S. M., and Rao, J. Y. 2007. Green tea induces 
annexin-I expression in human lung adenocarcinoma 
A549  cells: involvement of annexin-I in actin remodel-
ing. Laboratory Investigation 87(5):456–465. https://doi.
org/10.1038/labinvest.3700534
Luo, X., Yu, X., Liu, S., Deng, Q., Liu, X., Peng, S., Li, H., Liu, J., 
and Cao, Y. 2015. The role of targeting kinase activity 
by natural compounds in cancer chemoprevention and 
chemotherapy. Oncology Reports 34(2):547–554. https://
doi.org/10.3892/or.2015.4029
Ma, N., Luo, Y., Wang, Y., Liao, C., Ye, W. C., and Jiang, S. 2016 Se-
lective histone deacetylase inhibitors with anticancer ac-
tivity. Current Topics in Medicinal Chemistry 16(4):415–426. 
https://doi.org/10.2174/1568026615666150813145629
Manal, M., Chandrasekar, M., Jeyapal, G. P., and Nanjan, M. 
2016. Inhibitors of histone deacetylase as antitumor 
agents: A critical review. Bioorganic Chemistry 67:18–42. 
https://doi.org/10.1016/j.bioorg.2016.05.005
Marks, P. A. 2010. The clinical development of histone 
deacetylase inhibitors as targeted anticancer drugs. Ex-
pert Opinion on Investigational Drugs 19(9):1049–1066. 
https://doi.org/10.1517/13543784.2010.510514
Marquardt, J. U., Gomez-Quiroz, L., Arreguin Camacho, L. O., 
Pinna, F., Lee, Y. H., Kitade, M., Domínguez, M. P., Cast-
ven, D., Breuhahn, K., Conner, E. A., Galle, P. R., Ander-
sen, J. B., Factor, V. M., and Thorgeirsson, S. S. 2015. 
Curcumin effectively inhibits oncogenic NF-κB signaling 
and restrains stemness features in liver cancer. Journal 
of Hepatology 63(3):661–669. https://doi.org/10.1016/j.
jhep.2015.04.018
Mayboroda, A. A. 2013. Genes and proteins of oncogenesis. 
Sibirskiy meditsinskiy zhurnal 2:132–138. (In Russian)
Maze, I., Wenderski, W., Noh, K. M., Bagot, R. C., Tzavaras, N., 
et al. 2015. Critical role of histone turnover in neuronal 
transcription and plasticity. Neuron 87(1):77–94. https://
doi.org/10.1016/j.neuron.2015.06.014
Medina-Franco, J. L., López-Vallejo, F., Kuck, D., and Lyko, F. 
2011. Natural compounds as DNA methyltransferase 
inhibitors: a computer-aided discovery approach. Mo-
lecular Diversity 15(2):293–304. https://doi.org/10.1007/
s11030-010-9262-5
Meeran, S. M., Patel, S. N., and Tollefsbol, T. O. 2010. Sul-
foraphane causes epigenetic repression of human 
TERT expression in human breast cancer cell lines. 
PLoS One 5(7):e11457. https://doi.org/10.1371/journal.
pone.0011457
Minucci, S. and Pelicci, P. G. 2006. Histone deacetylase in-
hibitors and the promise of epigenetic (and more) 
treatments for cancer. Nature Reviews. Cancer 6:38–51. 
https://doi.org/10.1038/nrc1779
Mitani, T., Harada, N., Tanimori, S., Nakano, Y., Inui, H., and 
Yamaji, R. 2014. Resveratrol inhibits hypoxia-inducible 
factor-1α-mediated androgen receptor signaling and re-
presses tumor progression in castration-resistant pros-
tate cancer. Journal of Nutritional Science and Vitaminol-
ogy 60(4):276–282. https://doi.org/10.3177/jnsv.60.276
Mitani, T., Ito, Y., Harada, N., Nakano, Y., Inui, H., Ashida, H., 
and Yamaji, R. 2014. Resveratrol reduces the hypoxia-
induced resistance to doxorubicin in breast cancer cells. 
Journal of Nutritional Science and Vitaminology 60(2):122–
128. https://doi.org/10.3177/jnsv.60.122
Moghadamtousi, S. Z., Kadir, H. A., Paydar, M., Rouhollahi, E., 
and Karimian, H. 2014. Annona muricata leaves induced 
apoptosis in A549  cells through mitochondrial-medi-
ated pathway and involvement of NF-κB. BMC Comple-
mentary and Alternative Medicine 14:299. https://doi.
org/10.1186/1472-6882-14-299
Morey, L., Santanach, A., and Di Croce, L. 2015. Pluripotency 
and epigenetic factors in mouse embryonic stem cell 
fate regulation. Molecular and Cell Biology 35(16):2716–
2728. https://doi.org/10.1128/MCB.00266-15
Moseley, V. R., Morris, J., Knackstedt, R. W., and Wargovich, 
M. J. 2013. Green tea polyphenol epigallocatechin. Anti-
cancer Research 33(12):5325–5333.
Mudduluru, G., George-William, J. N., Muppala, S., Asan-
gani, I. A., Kumarswamy, R., Nelson, L. D., and Allgayer, H. 
2011. Curcumin regulates miR-21 expression and inhib-
its invasion and metastasis in colorectal cancer. Biosci-
ence Reports 31(3):185–197. https://doi.org/10.1042/
BSR20100065
Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Panta-
zis, P., and Aggarwal, B. B. 2001. Curcumin downregu-
lates cell survival mechanisms in human prostate can-
cer cell lines. Oncogene 20(52):7597–7609. https://doi.
org/10.1038/sj.onc.1204997
Murugan, R. S., Vinothini, G., Hara, Y., and Nagini, S. 2009. 
Black tea polyphenols target matrix metalloproteinases, 
RECK, proangiogenic molecules and histone deacety-
lase in a rat hepatocarcinogenesis model. Anticancer Re-
search 29(6):2301–2305.
Nakayama, J., Rice, J. C., Strahl, B. D., Allis, C. D., and Gre-
wal, S. I. 2001. Role of histone H3  lysine 9 methylation 
in epigenetic control of heterochromatin assembly. 
328 BIOLOGICAL  COMMUNICATIONS,  vol. 65,  issue 4,  October–December,  2020 | https://doi.org/10.21638/spbu03.2020.405
Science 292(5514):110–113. https://doi.org/10.1126/sci-
ence.1060118
Nandakumar, V., Vaid, M., and Katiyar, S. K. 2011. (-)-Epigal-
locatechin-3-gallate reactivates silenced tumor sup-
pressor genes, Cip1/p21  and p16INK4a, by reducing 
DNA methylation and increasing histones acetylation in 
human skin cancer cells. Carcinogenesis 32(4):537–544. 
https://doi.org/10.1093/carcin/bgq285
Neergheen-Bhujun, V., Taj Awan, A., Baran, Y., et al. 2017. Bio-
diversity, drug discovery, and the future of global health: 
Introducing the biodiversity to biomedicine consortium, 
a call to action. Journal of Global Health 7(2):020304. 
https://doi.org/10.7189/jogh.07.020304
Newman, D. J. and Cragg, G. M. 2007. Natural products as 
sources of new drugs over the last 25 years. Journal of 
Natural Products 70(3):461–477. https://doi.org/10.1021/
np068054v
Orlikova, B., Schumacher, M., Juncker, T., Yan, C. C., Inayat-
Hussain, S. H., Hajjouli, S., Cerella, C., Dicato, M., and 
Diederich, M. 2013. Styryl-lactone goniothalamin inhib-
its TNF-α-induced NF-κB activation. Food and Chemical 
Toxicology: An International Journal Published for the Brit-
ish Industrial Biological Research Association 59:572–578. 
https://doi.org/10.1016/j.fct.2013.06.051
Pandey, M., Shukla, S., and Gupta, S. 2010. Promoter demeth-
ylation and chromatin remodeling by green tea polyphe-
nols leads to re-expression of GSTP1 in human prostate 
cancer cells. International Journal of Cancer 126(11):2520–
2533. https://doi.org/10.1002/ijc.24988
Park, C. H., Lee, J. H., and Yang, C. H. 2005. Curcumin deriva-
tives inhibit the formation of Jun-Fos-DNA complex in-
dependently of their conserved cysteine residues. Jour-
nal of Biochemistry and Molecular Biology 38(4):474–480. 
https://doi.org/10.5483/BMBRep.2005.38.4.474
Paszkowski, J. and Whitham, S. 2001. Gene silencing and 
DNA methylation processes. Current Opinion in Plant 
Biology 4(2):123–129. https://doi.org/10.1016/S1369-
5266(00)00147-3
Pera, B., Tang, T., Marullo, R., Yang, S. N., Ahn, H., Patel, J., El-
strom, R., Ruan, J., Furman, R., Leonard, J., Cerchietti, L., 
and Martin, P. 2016. Combinatorial epigenetic therapy in 
diffuse large B cell lymphoma pre-clinical models and pa-
tients. Clinical Epigenetics 8:79. https://doi.org/10.1186/
s13148-016-0245-y
Pietrocola, F., Mariño, G., Lissa, D., Vacchelli, E., Malik, S. A., 
Niso-Santano, M., Zamzami, N., Galluzzi, L., Maiuri, M. C., 
and Kroemer, G. 2012. Pro-autophagic polyphenols re-
duce the acetylation of cytoplasmic proteins. Cell Cycle 
11(20):3851–3860. https://doi.org/10.4161/cc.22027
Pradhan, S. J., Mishra, R., Sharma, P., and Kundu, G. C. 2010. 
Quercetin and sulforaphane in combination suppress 
the progression of melanoma through the down-
regulation of matrix metalloproteinase-9. Experimen-
tal and Therapeutic Medicine 1(6):915–920. https://doi.
org/10.3892/etm.2010.144
Pratheeshkumar, P., Sreekala, C., Zhang, Z., Budhraja, A., 
Ding, S., Son, Y. O., Wang, X., Hitron, A., Hyun-Jung, K., 
Wang, L., Lee, J. C., and Shi, X. 2012. Cancer preven-
tion with promising natural products: mechanisms 
of action and molecular targets. Anticancer Agents in 
Medicinal Chemistry 12(10):1159–1184. https://doi.
org/10.2174/187152012803833035
Prusty, B. K. and Das, B. C. 2005. Constitutive activation of 
transcription factor AP-1 in cervical cancer and suppres-
sion of human papillomavirus (HPV) transcription and 
AP-1 activity in HeLa cells by curcumin. International Jour-
nal of Cancer 113(6):951–960. https://doi.org/10.1002/
ijc.20668
Rahman, K. M., Sarkar, F. H., Banerjee, S., Wang, Z., Liao, D. J., 
Hong, X., and Sarkar, N. H. 2006. Therapeutic interven-
tion of experimental breast cancer bone metastasis by 
indole-3-carbinol in SCID-human mouse model. Molec-
ular Cancer Therapeutics 5(11):2747–2756. https://doi.
org/10.1158/1535-7163.MCT-06-0221
Rea, S., Eisenhaber, F., O’Carroll, D., Strahl, B. D., Sun, Z. W., 
Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Al-
lis, C. D., and Jenuwein, T. 2000. Regulation of chro-
matin structure by site-specific histone H3  methyl-
transferases. Nature 406(6796):593–599. https://doi.
org/10.1038/35020506
Roy, S. K., Chen, Q., Fu, J., Shankar, S., and Srivastava, R. K. 
2011. Resveratrol inhibits growth of orthotopic pancre-
atic tumors through activation of FOXO transcription 
factors. PLoS One 6(9):e25166. https://doi.org/10.1371/
journal.pone.0025166
Royston, K. J. and Tollefsbol, T. O. 2015. The epigenetic im-
pact of cruciferous vegetables on cancer prevention. 
Current Pharmacology Reports 1(1):46–51. https://doi.
org/10.1007/s40495-014-0003-9
Rummun, N., Hughes, R. E., Beesoo, R., Li, W. W., et al. 2019. 
Mauritian endemic medicinal plant extracts induce 
G2/M phase cell cycle arrest and growth inhibition of 
oesophageal squamous cell carcinoma in vitro. Acta Na-
turae 11(1):81–90. https://doi.org/10.32607/20758251-
2019-11-1-81-90
Safa, M., Tavasoli, B., Manafi, R., Kiani, F., Kashiri, M., Ebra-
himi, S., and Kazemi, A. 2015. Indole-3-carbinol sup-
presses NF-κB activity and stimulates the p53 pathway 
in pre-B acute lymphoblastic leukemia cells. Tumour Biol-
ogy: The Journal of the International Society for Oncodevel-
opmental Biology and Medicine 36(5):3919–3930. https://
doi.org/10.1007/s13277-014-3035-1
Saha, K., Hornyak, T. J., and Eckert, R. L. 2013. Epigenetic 
cancer prevention mechanisms in skin cancer. An Of-
ficial Journal of the American Association of Pharmaceuti-
cal Scientists 15(4):1064–1071. https://doi.org/10.1208/
s12248-013-9513-3
Samantarrai, D., Dash, S., Chhetri, B., and Mallick, B. 2013. 
Genomic and epigenomic cross-talks in the regulatory 
landscape of miRNAs in breast cancer. Molecular Cancer 
Research 4:315–328. https://doi.org/10.1158/1541-7786
Santos, F. P., Kantarjian, H., Garcia-Manero, G., Issa, J. P., and 
Ravandi, F. 2010. Decitabine in the treatment of myelo-
dysplastic syndromes. Expert Review of Anticancer Thera-
py 10(1):9–22. https://doi.org/10.1586/era.09.164
Schubert, T. and Langst, G. 2015. Study of epigenetic inter-
actions using Microscale Thermophoresis (MST). AIMS 
Biophysics 2(3):370–380. https://doi.org/10.3934/bio-
phy.2015.3.370
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., 
and Kurdistani, S. K. 2005. Global histone modification 
patterns predict risk of prostate cancer recurrence. Na-
ture 435(7046):1262–1266. https://doi.org/10.1038/na-
ture03672
Shankar, S., Nall, D., Tang, S. N., Meeker, D., Passarini, J., 
Sharma, J., and Srivastava, R. K. 2011. Resveratrol inhib-
its pancreatic cancer stem cell characteristics in human 
and KrasG12D transgenic mice by inhibiting pluripoten-
cy maintaining factors and epithelial-mesenchymal tran-
sition. PLoS One 6(1):e16530. https://doi.org/10.1371/
journal.pone.0016530
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., 
Ke, X., Huang, H., Shen, Z., Fan, Y., Li, W., Zhao, X., et al. 
2015. Results from a multicenter, open-label, pivotal 
phase II study of chidamide in relapsed or refractory 
peripheral T-cell lymphoma. Annals of Oncology: Of-









ficial Journal of the European Society for Medical Oncol-
ogy 26(8):1766–1771. https://doi.org/10.1093/annonc/
mdv237
Shukla, S., Meeran, S. M., and Katiyar, S. K. 2014. Epigenetic 
regulation by selected dietary phytochemicals in cancer 
chemoprevention. Cancer Letters 355(1):9–17. https://
doi.org/10.1016/j.canlet.2014.09.017
Siddiqui, I. A., Adhami, V. M., Saleem, M., and Mukhtar, H. 
2006.Beneficial effects of tea and its polyphenols against 
prostate cancer. Molecular Nutrition & Food Research 
50(2):130–143. https://doi.org/10.1002/mnfr.200500113
Song, J., Noh, J. H., Lee, J. H., Eun, J. W., Ahn, Y. M., Kim, S. Y., 
Lee, S. H., et al. 2005. Increased expression of his-
tone deacetylase 2  is found in human gastric can-
cer. APMIS: Acta Pathologica, Microbiologica, et Im-
munologica Scandinavica 113(4):264–268. https://doi.
org/10.1111/j.1600-0463.2005.apm_04.x
Su, Z. Y., Khor, T. O., Shu, L., Lee, J. H., Saw, C. L., Wu, T. Y., 
Huang, Y., et al. 2013. Epigenetic reactivation of Nrf2 in 
murine prostate cancer TRAMP C1 cells by natural phy-
tochemicals Z-ligustilide and Radix angelica sinensis 
via promoter CpG demethylation. Chemical Research 
in Toxicology 26(3):477–485. https://doi.org/10.1021/
tx300524p
Subramaniam, D., Ponnurangam, S., Ramamoorthy, P., 
Standing, D., Battafarano, R. J., Anant, S., and Shar-
ma, P. 2012. Curcumin induces cell death in esopha-
geal cancer cells through modulating Notch signaling. 
PloS One 7(2):e30590. https://doi.org/10.1371/journal.
pone.0030590
Sui, X., Zhu, J., Zhou, J., et al. 2015. Epigenetic modifications 
as regulatory elements of autophagy in cancer. Cancer 
Letters 360(2):106–113. https://doi.org/10.1016/j.can-
let.2015.02.009
Sun, L., Zhou, W., Zhang, H., Guo, Q., Yang, W., Li, B., Sun, Z., 
Gao, S., and Cui, R. 2019. Modulation of multiple sig-
naling pathways of the plant-derived natural products 
in cancer. Frontiers in Oncology 9:1153. https://doi.
org/10.3389/fonc.2019.01153
Sutherland, J. and Costa, M. 2003. Epigenetics and the en-
vironment. Annals of the New York Academy of Sciences 
983:151–160. https://doi.org/10.1111/j.1749-6632.2003.
tb05970.x
Taby, R. and Issa, J. P. 2010. Cancer epigenetics. CA: A Can-
cer Journal for Clinicians 60(6):376–392. https://doi.
org/10.3322/caac.20085
Teif, V. and Rippe, K. 2011. Nucleosome mediated cross-
talk between transcription factors at eukaryotic en-
hancers. Physical Biology 8(4):044001. https://doi.
org/10.1088/1478-3975/8/4/044001
Teiten, M. H., Eifes, S., Dicato, M., and Diederich, M. 2010. 
Curcumin  — the paradigm of a multi-target natural 
compound with applications in cancer prevention and 
treatment. Toxins 2(1):128–162. https://doi.org/10.3390/
toxins2010128
Teiten, M. H., Gaascht, F., Eifes, S., Dicato, M., and Died-
erich, M. 2010. Chemopreventive potential of curcumin 
in prostate cancer. Genes & Nutrition 5(1):61–74. https://
doi.org/10.1007/s12263-009-0152-3
Thakur, V. S., Deb, G., Babcook, M. A., and Gupta, S. 2014. 
Plant phytochemicals as epigenetic modulators: role in 
cancer chemoprevention. The AAPS Journal 16(1):151–
163. https://doi.org/10.1208/s12248-013-9548-5
Toden, S., Okugawa, Y., Buhrmann, C., Nattamai, D., Angui-
ano,  E., Baldwin, N., Shakibaei, M., Boland, C. R., and 
Goel,  A. 2015. Novel evidence for curcumin and bo-
swellic acid-induced chemoprevention through regu-
lation of miR-34a and miR-27a in colorectal cancer. 
Cancer Prevention Research 8(5):431–443. https://doi.
org/10.1158/1940-6207.CAPR-14-0354
Traka, M., Gasper, A. V., Smith, J. A., Hawkey, C. J., Bao, Y., and 
Mithen, R. F. 2005. Transcriptome analysis of human 
colon Caco-2 cells exposed to sulforaphane. The Journal 
of Nutrition 135(8):1865–1872. https://doi.org/10.1093/
jn/135.8.1865
Tuntiwechapikul, W., Taka, T., Songsomboon, C., Kaewtun-
jai,  N., Imsumran, A., Makonkawkeyoon, L., Pompi-
mon,  W., and Lee, T. R. 2010. Ginger extract inhibits 
human telomerase reverse transcriptase and c-Myc ex-
pression in A549 lung cancer cells. Journal of Medical Food 
13(6):1347–1354. https://doi.org/10.1089/jmf.2010.1191
Udugama, M., Chang, F. T. M., Chan, F. L., et al. 2015. His-
tone variant H3.3 provides the heterochromatic H3  ly-
sine 9  tri-methylation mark at telomeres. Nucleic Acids 
Research 43(21):10227–10237. https://doi.org/10.1093/
nar/gkv847
Urnov, F. D. and Wolffe, A. P. 2001. Above and within the ge-
nome: epigenetics past and present. Journal of Mamma-
ry Gland Biology and Neoplasia 6(2):153–167. https://doi.
org/10.1023/A:1011304606604
Venkatasubramani, A. V., McLaughlin, K., Blanco, R. G., Lari-
onov V., and Kagansky, A. 2015. The pilot screening RNA 
using the system based on mammalian cells reveals 
new putative silencing factors, including Kat5  /  Tip60. 
AIMS Biophysics 2(4):570–584. https://doi.org/10.3934/
biophy.2015.4.570
Verhoeven, D. T., Verhagen, H., Goldbohm, R. A., van den 
Brandt, P. A., van Poppel, G. 1997. A review of mecha-
nisms underlying anticarcinogenicity by brassica veg-
etables Chemico-biological Interactions 103(2):79–129. 
https://doi.org/10.1016/s0009-2797(96)03745-3
Volate, S. R., Muga, S. J., Issa, A. Y., Nitcheva, D., Smith, T., and 
Wargovich, M. J. 2009. Epigenetic modulation of the reti-
noid X receptor alpha by green tea in the azoxymethane-
Apc Min/+ mouse model of intestinal cancer. Molecular 
Carcinogenesis 48(10):920–933. https://doi.org/10.1002/
mc.20542
Wai-Leng, L., Jing-Ying, H., and Lie-Fen, S. 2013. Phytoag-
ents for cancer management: Regulation of nucleic 
acid oxidation, ROS, and related mechanisms. Oxida-
tive Medicine and Cellular Longevity 925804. https://doi.
org/10.1155/2013/925804
Wang, J., Xie, H., Gao, F., Zhao, T., Yang, H., and Kang, B. 2016. 
Curcumin induces apoptosis in p53-null Hep3B cells 
through a TAp73/DNp73-dependent pathway. Tumour 
biology: The Journal of the International Society for On-
codevelopmental Biology and Medicine 37(3):4203–4212. 
https://doi.org/10.1007/s13277–015–4029–3
Wang, L. G., Beklemisheva, A., Liu, X. M., Ferrari, A. C., Feng, J., 
and Chiao, J. W. 2007. Dual action on promoter demeth-
ylation and chromatin by an isothiocyanate restored 
GSTP1 silenced in prostate cancer Molecular Carcinogen-
esis 46(1):24–31. https://doi.org/10.1002/mc.20258
Wang, L., Liou, J., Li, Y., Liu, Y., Pan, S., and Teng, C. 2014. A 
novel class I HDAC inhibitor, MPT0G030, induces cell 
apoptosis and differentiation in human colorectal can-
cer cells via HDAC1/PKCδ and E-cadherin. Oncotarget 
5:5651–5662. https://doi.org/10.18632/oncotarget.2155
Wang, Y., Li, Y., Liu, X., and Cho, W. C. 2013. Genetic and epi-
genetic studies for determining molecular targets of nat-
ural compound anticancer agents. Current Cancer Drug 
Targets 13(5):506–518. https://doi.org/10.2174/1568009
6113139990033
Weichert, W., Roske, A., Niesporek, S., Noske, A., Buckend-
ahl, A. C., Dietel, M., Gekeler, V., Boehm, M., Beckers, T., 
and Denkert, C. 2008. Class I histone deacetylase ex-
330 BIOLOGICAL  COMMUNICATIONS,  vol. 65,  issue 4,  October–December,  2020 | https://doi.org/10.21638/spbu03.2020.405
pression has independent prognostic impact in hu-
man colorectal cancer: specific role of class I histone 
deacetylases in vitro and in vivo. Clinical Cancer Research 
14(6):1669–1677. https://doi.org/10.1158/1078-0432
West, A. C. and Johnstone, R. W. 2014. New and emerging 
HDAC inhibitors for cancer treatment. The Journal of Clin-
ical Investigation 124(1):30–39. https://doi.org/10.1172/
JCI69738
Wilson, A. J., Byun, D. S., Popova, N., Murray, L. B., L’Italien, K., 
Sowa, Y., et al. 2006. Histone deacetylase 3 (HDAC3) and 
other class I HDACs regulate colon cell maturation and 
p21  expression and are deregulated in human colon 
cancer. The Journal of Biological Chemistry 281(19):13548–
13558. https://doi.org/10.1074/jbc.M510023200
Wong, C. P., Hsu, A., Buchanan, A., Palomera-Sanchez, Z., 
Beaver, L. M., Houseman, E. A., Williams, D. E., Dash-
wood,  R. H., and Ho, E. 2014. Effects of sulforaphane 
and 3,3’-diindolylmethane on genome-wide promoter 
methylation in normal prostate epithelial cells and 
prostate cancer cells. PLoS One 9(1):e86787. https://doi.
org/10.1371/journal.pone.0086787
Woo, H. J., Lee, S. J., Choi, B. T., Park, Y. M., and Choi, Y. H. 2007. 
Induction of apoptosis and inhibition of telomerase ac-
tivity by trichostatin A, a histone deacetylase inhibitor, 
in human leukemic U937  cells. Experimental and Mo-
lecular Pathology 82(1):77–84. https://doi.org/10.1016/j.
yexmp.2006.02.004
Xiao, G. S., Jin, Y. S., Lu, Q. Y., Zhang, Z. F., Belldegrun, A. et al. 
2007. Annexin-I as a potential target for green tea extract 
induced actin remodeling. International Journal of Cancer 
120(1):111–120. https://doi.org/10.1002/ijc.22164
Ye, M., Zhang, J., Zhang, J., Miao, Q., Yao, L., and Zhang, J. 
2015. Curcumin promotes apoptosis by activating the 
p53-miR-192-5p/215-XIAP pathway in non-small cell 
lung cancer. Cancer Letters 357(1):196–205. https://doi.
org/10.1016/j.canlet.2014.11.028
Yoon, D. S., Choi, Y., Jang, Y., Lee, M., Choi, W. J., Kim, S. H., and 
Lee, J. W. 2014. SIRT1 directly regulates SOX2 to maintain 
self-renewal and multipotency in bone marrow-derived 
mesenchymal stem cells. Stem Cells 32(12):3219–3231. 
https://doi.org/10.1002/stem.1811
Yu, X. D. and Guo, Z. S. 2010 Epigenetic drugs for cancer treat-
ment and prevention: mechanisms of action. Biomolecu-
lar Concepts 1(3–4):239–251. https://doi.org/10.1515/
bmc.2010.020
Zang, S., Liu, T., Shi, J., and Qiao, L. 2014. Curcumin: a promis-
ing agent targeting cancer stem cells. Anti-cancer Agents 
in Medicinal Chemistry 14(6):787–792. https://doi.org/10.
2174/1871520614666140521114735
Zaridze, D. G. 2004  in Carcinogenesis (Zaridze, D. G., ed.), 
Meditsina, Moscow, pp. 29–85. (In Russian)
Zhang, M., Bian, Z. G., Zhang, Y., Wang, J. H., Kan, L., Wang, X., 
Niu, H. Y., He, P. 2014. Cucurbitacin B inhibits prolifera-
tion and induces apoptosis via STAT3  pathway inhibi-
tion in A549 lung cancer cells. Molecular Medicine Reports 
10(6):2905–2911. https://doi.org/10.3892/mmr.2014.2581
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., 
Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., and 
Iwase, H. 2005. Quantitation of HDAC1  mRNA expres-
sion in invasive carcinoma of the breast*. Breast Can-
cer Research and Treatment 94(1):11–16. https://doi.
org/10.1007/s10549-005-6001-1
Zhao, Y., Tan, J., Zhuang, L., Jiang, X., Liu, E. T., and Yu, Q. 
2005. Inhibitors of histone deacetylases target the 
Rb-E2F1  pathway for apoptosis induction through ac-
tivation of proapoptotic protein Bim. Proceedings of 
the National Academy of Sciences of the United States of 
America 102:16090–16095. https://doi.org/10.1073/
pnas.0505585102
Zhdanov, R., Schirmer, E. C., Venkatasubramani A. V., et al. 2015. 
Lipids contribute to epigenetic control via chromatin struc-
ture and functions. Science Open Research 10(15). https://
doi.org/10.14293/S2199-1006.1.SOR-LIFE.AUXYTR.v1
Zhu, P., Martin, E. Mengwasser, J., Schlag, P., Janssen, K. P., 
and Gottlicher, M. 2004. Induction of HDAC2  expres-
sion upon loss of APC in colorectal tumorigenesis. Can-
cer Cell 5(5):455–463. https://doi.org/10.1016/S1535-
6108(04)00114-X
Zwergel, C., Valente, S., Jacob, C., and Mai, A. 2015. Emerging 
approaches for histone deacetylase inhibitor drug dis-
covery. Expert Opinion on Drug Discovery 10(6):599–613. 
https://doi.org/10.1517/17460441.2015.1038236
